Europe Left Ventricular Assist Device (LVAD) Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 58
1.1 OBJECTIVES OF THE STUDY 58
1.2 MARKET DEFINITION 58
1.3 OVERVIEW OF EUROPE LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET 58
1.4 LIMITATIONS 61
1.5 MARKETS COVERED 61
2 MARKET SEGMENTATION 65
2.1 MARKETS COVERED 65
2.2 GEOGRAPHICAL SCOPE 66
2.3 YEARS CONSIDERED FOR THE STUDY 67
2.4 CURRENCY AND PRICING 67
2.5 DBMR TRIPOD DATA VALIDATION MODEL 68
2.6 MULTIVARIATE MODELLING 71
2.7 PRODUCT TYPE LIFELINE CURVE 71
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 72
2.9 DBMR MARKET POSITION GRID 73
2.10 MARKET END USER COVERAGE GRID 74
2.11 VENDOR SHARE ANALYSIS 75
2.12 SECONDARY SOURCES 76
2.13 ASSUMPTIONS 76
3 EXECUTIVE SUMMARY 77
4 PREMIUM INSIGHTS 80
4.1 PESTEL 82
4.2 PORTER'S 83
4.3 INDUSTRIAL INSIGHTS: 84
5 EUROPE LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: REGULATIONS 85
5.1 REGULATION IN U.S. 85
5.1.1 GUIDELINES- 85
5.2 REGULATION IN EUROPE 86
5.2.1 GUIDELINES FOR THE MANUFACTURERS: 86
5.3 REGULATION IN CANADA 86
5.3.1 GUIDELINES FOR THE MANUFACTURERS: 86
5.4 REGULATION IN MEXICO 87
5.4.1 GUIDELINES FOR THE MANUFACTURERS: 87

6 MARKET OVERVIEW 88
6.1 DRIVERS 90
6.1.1 INCREASING GERIATRIC POPULATION ALONG WITH RISING PREVALENCE OF CARDIAC DISEASES 90
6.1.2 PRESENCE OF FAVOURABLE REIMBURSEMENT POLICIES 91
6.1.3 CHANGING LIFESTYLE TRIGGERS THE DEVELOPMENT OF CARDIOVASCULAR DISEASES 91
6.2 RESTRAINTS 92
6.2.1 HIGH COST OF LVAD IMPLANTATION AND TREATMENT 92
6.2.2 COMPLICATIONS AND RISKS ASSOCIATED WITH LVAD 93
6.3 OPPORTUNITIES 93
6.3.1 INCREASE IN HEALTHCARE EXPENDITURE 93
6.3.2 INCREASE IN MINIMALLY INVASIVE PROCEDURE 94
6.3.3 INCREASING SHORTAGE OF ORGAN DONORS 94
6.3.4 TECHNOLOGICAL ADVANCEMENTS IN LEFT VENTRICULAR ASSIST DEVICES 95
6.4 CHALLENGES 95
6.4.1 ONGOING COVID-19 95
6.4.2 INCREASE IN PRODUCT RECALL 96
7 EUROPE LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY PRODUCT TYPE 97
7.1 OVERVIEW 98
7.2 HEART PUMP 101
7.3 CONTROLLER 101
7.4 BATTERIES 102
7.4.1 RECHARGEABLE 103
7.4.2 NON-RECHARGEABLE 103
7.5 WIRES 103
8 EUROPE LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY 105
8.1 OVERVIEW 106
8.2 BRIDGE-TO-TRANSPLANT (BTT) THERAPY 109
8.2.1 HEART PUMP 110
8.2.2 CONTROLLER 110
8.2.3 BATTERIES 110
8.2.4 WIRES 110
8.3 DESTINATION THERAPY 110
8.3.1 HEART PUMP 111
8.3.2 CONTROLLER 111
8.3.3 BATTERIES 112
8.3.4 WIRES 112

8.4 BRIDGE-TO-CANDIDACY (BTC) THERAPY 112
8.4.1 HEART PUMP 113
8.4.2 CONTROLLER 113
8.4.3 BATTERIES 113
8.4.4 WIRES 114
8.5 BRIDGE-TO-RECOVERY (BTR) THERAPY 114
8.5.1 HEART PUMP 115
8.5.2 CONTROLLER 115
8.5.3 BATTERIES 115
8.5.4 WIRES 115
9 EUROPE LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY AGE GROUP 116
9.1 OVERVIEW 117
9.2 ADULT 120
9.2.1 19-39 YEARS 121
9.2.2 40-59 YEARS 121
9.2.3 60-79 YEARS 121
9.2.4 ABOVE 80 YEARS 121
9.3 PEDIATRIC 121
10 EUROPE LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY GENERATION 123
10.1 OVERVIEW 124
10.2 SECOND GENERATION DEVICES 127
10.3 THIRD GENERATION DEVICES 127
10.4 FIRST GENERATION DEVICES 128
11 EUROPE LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY DESIGN 130
11.1 OVERVIEW 131
11.2 AXIAL 134
11.3 CENTRIFUGAL 134
12 EUROPE LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION 136
12.1 OVERVIEW 137
12.2 CONGESTIVE HEART FAILURE 140
12.2.1 HEART PUMP 141
12.2.2 CONTROLLER 141
12.2.3 BATTERIES 141
12.2.4 WIRES 141

12.3 CONGENITAL HEART DISEASE 141
12.3.1 HEART PUMP 142
12.3.2 CONTROLLER 142
12.3.3 BATTERIES 142
12.3.4 WIRES 143
12.4 MYOCARDITIS 143
12.4.1 HEART PUMP 144
12.4.2 CONTROLLER 144
12.4.3 BATTERIES 144
12.4.4 WIRES 144
12.5 CARDIAC ARREST 144
12.5.1 HEART PUMP 145
12.5.2 CONTROLLER 145
12.5.3 BATTERIES 146
12.5.4 WIRES 146
12.6 FAMILIAL ARRHYTHMIAS AND ARRHYTHMIC CARDIOMYOPATHIES 146
12.6.1 HEART PUMP 147
12.6.2 CONTROLLER 147
12.6.3 BATTERIES 147
12.6.4 WIRES 148
12.7 ADVANCED HEART FAILURE 148
12.7.1 HEART PUMP 149
12.7.2 CONTROLLER 149
12.7.3 BATTERIES 149
12.7.4 WIRES 149
12.8 OTHERS 149
13 EUROPE LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET, BY DURABILITY 151
13.1 OVERVIEW 152
13.2 LONG-TERM 155
13.3 INTERMEDIATE-TERM 155
13.4 SHORT-TERM 156
14 EUROPE LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET, BY PULSE TYPE 158
14.1 OVERVIEW 159
14.2 NONPULSATILE 162
14.3 PULSATILE 162
15 EUROPE LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET, BY END USER 164
15.1 OVERVIEW 165
15.2 HOSPITAL 168
15.3 CARDIAC CATH LABORATORIES 168
15.4 SPECIALTY CLINICS 169
15.5 OTHERS 170
16 EUROPE LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET, BY DISTRIBUTION CHANNEL 172
16.1 OVERVIEW 173
16.2 DIRECT TENDER 176
16.3 RETAIL SALES 176
16.4 OTHERS 177
17 EUROPE LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY REGION 178
17.1 EUROPE 179
17.1.1 GERMANY 192
17.1.2 FRANCE 198
17.1.3 U.K. 204
17.1.4 ITALY 210
17.1.5 RUSSIA 216
17.1.6 SPAIN 222
17.1.7 TURKEY 228
17.1.8 NETHERLANDS 234
17.1.9 SWITZERLAND 240
17.1.10 BELGIUM 246
17.1.11 IRELAND 252
17.1.12 REST OF EUROPE 258
18 EUROPE LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: COMPANY LANDSCAPE 259
18.1 COMPANY SHARE ANALYSIS: EUROPE 259
19 SWOT ANALYSIS 260

20 COMPANY PROFILE 261
20.1 ABIOMED 261
20.1.1 COMPANY SNAPSHOT 261
20.1.2 REVENUE ANALYSIS 261
20.1.3 COMPANY SHARE ANALYSIS 262
20.1.4 PRODUCT PORTFOLIO 262
20.1.5 RECENT DEVELOPMENTS 263
20.1.5.1 FDA APPROVAL 263
20.1.5.2 FDA APPROVAL 263
20.2 ABBOTT 264
20.2.1 COMPANY SNAPSHOT 264
20.2.2 REVENUE ANALYSIS 264
20.2.3 COMPANY SHARE ANALYSIS 265
20.2.4 PRODUCT PORTFOLIO 265
20.2.5 RECENT DEVELOPMENTS 265
20.2.5.1 SUPPLY INCREMENT 265
20.2.5.2 BREAK THROUGH DEVICE DESIGNATION 266
20.3 BERLIN HEART 267
20.3.1 COMPANY SNAPSHOT 267
20.3.2 COMPANY SHARE ANALYSIS 267
20.3.3 PRODUCT PORTFOLIO 268
20.3.4 RECENT DEVELOPMENT 268
20.3.4.1 PRODUCT APPROVAL 268
20.4 SAFT (A SUBSIDIARY OF TOTALENERGIES) 269
20.4.1 COMPANY SNAPSHOT 269
20.4.2 REVENUE ANALYSIS 269
20.4.3 COMPANY SHARE ANALYSIS 270
20.4.4 PRODUCT PORTFOLIO 270
20.4.5 RECENT DEVELOPMENT 270
20.4.5.1 PARTNERSHIP 270
20.5 JARVIK HEART, INC. 271
20.5.1 COMPANY SNAPSHOT 271
20.5.2 COMPANY SHARE ANALYSIS 271
20.5.3 PRODUCT PORTFOLIO 271
20.5.4 RECENT DEVELOPMENT 272
20.5.4.1 FDA APPROVAL 272

20.6 CORWAVE SA 273
20.6.1 COMPANY SNAPSHOT 273
20.6.2 PRODUCT PORTFOLIO 273
20.6.3 RECENT DEVELOPMENT 273
20.6.3.1 EXPANSION 273
20.7 EVAHEART, INC 274
20.7.1 COMPANY SNAPSHOT 274
20.7.2 PRODUCT PORTFOLIO 274
20.7.3 RECENT DEVELOPMENT 274
20.7.3.1 PRODUCT TRIAL 274
21 QUESTIONNAIRE 275
22 RELATED REPORTS 280